Is Celldex's US$300 Million Follow-On To Fund Barzolvolimab Altering The Investment Case For CLDX? [Yahoo! Finance]
Celldex Therapeutics, Inc. (CLDX)
Last celldex therapeutics, inc. earnings: 11/12 08:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.celldex.com
Company Research
Source: Yahoo! Finance
The raise closely follows encouraging Phase 2 barzolvolimab data in chronic urticaria, underscoring how investor capital is being directed toward late-stage, potentially disease-modifying assets. We'll now examine how funding barzolvolimab's commercial readiness shapes Celldex's investment narrative and longer-term positioning in immuno-dermatology. The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. What Is Celldex Therapeutics' Investment Narrative? To own Celldex today, you really have to believe barzolvolimab can transition from compelling Phase 2 data in chronic urticarias to a real commercial franchise, and that management can fund that journey without excessively diluting you. The latest US$300.01 million follow-on offering shores up the balance sheet ahead of pivotal Phase 3 CSU readouts and potential launch prep, reinforcing the near term catalyst stack around barzolv
Show less
Read more
Impact Snapshot
Event Time:
CLDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDX alerts
High impacting Celldex Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDX
News
- Celldex to Present at Upcoming Investor ConferenceGlobeNewswire
- Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch [Seeking Alpha]Seeking Alpha
- Celldex Announces Pricing of $300 Million Public Offering of Common Stock [Yahoo! Finance]Yahoo! Finance
- Celldex Announces Pricing of $300 Million Public Offering of Common StockGlobeNewswire
CLDX
Earnings
- 2/25/26 - Miss
CLDX
Sec Filings
- 4/2/26 - Form 424B5
- 4/2/26 - Form 8-K
- 4/1/26 - Form 424B5
- CLDX's page on the SEC website